Edwards Lifesciences (EW) Receivables (2009 - 2026)

Edwards Lifesciences' Receivables history runs 18 years deep, the most recent figure standing at $973.0 million for Q1 2026.

• On a quarterly basis, Receivables rose 29.41% year-over-year to $973.0 million in Q1 2026; TTM through Mar 2026 was $973.0 million, a 29.41% increase from a year earlier, with the FY2025 full-year figure at $912.1 million, up 25.39% from the prior year.
• Receivables improved to $973.0 million in Q1 2026 per EW's latest filing, from $912.1 million in the prior quarter.
• Across five years, Receivables topped out at $973.0 million in Q1 2026 and bottomed at $661.4 million in Q3 2022.
• The 5-year median for Receivables is $811.5 million (2024), against an average of $802.1 million.
• Across the five-year window, Receivables retreated 14.25% in 2025 and increased 29.41% in 2026, its largest moves.
• Year by year, Receivables stood at $699.1 million in 2022, then advanced by 18.45% to $828.1 million in 2023, then fell by 12.16% to $727.4 million in 2024, then advanced by 25.39% to $912.1 million in 2025, then increased by 6.68% to $973.0 million in 2026.
• Per Business Quant, the three latest EW Receivables figures stand at $973.0 million (Q1 2026), $912.1 million (Q4 2025), and $892.8 million (Q3 2025).